Back to Report Store Home

Respiratory Syncytial Virus and Human Parainfluenza Virus 3 Infections Drug Development Pipeline Review, 2018

  • Published: Apr-2018
  • Report Code: GBIHC033IDB
  • Report Format: pdf

Description

This report provides an overview of the pipeline landscape for the respiratory tract infections respiratory syncytial virus (RSV) and human parainfluenza virus 3 (HPIV-3). It provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for RSV and HPIV-3 infections, and features dormant and discontinued products.

RSV infects the lungs and breathing passages. Symptoms include cough, stuffy or runny nose, mild sore throat, earache and fever. HPIV-3 is a life-threatening infection that causes respiratory illnesses in infants and young children. Symptoms include fever, cough runny nose, croup, bronchiolitis, wheezing and sore throat.

Scope

  • Which companies are the most active within the pipeline for RSV and HPIV-3 infections?

  • Which pharmaceutical approaches are most prominent at each stage of the pipeline and within each indication?

  • To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies?

  • What are the most important R&D milestones and data publications to have happened within this field?

Reasons To Buy

  • Understand the overall pipeline, with an at-a-glance overview of all products in therapeutic development for each indication

  • Assess the products in development in granular detail, with an up-to-date overview of each individual pipeline program in each indication, and a comprehensive picture of recent updates and milestones for each

  • Analyze the companies, institutions and universities currently operating in the pipeline, and the products being fielded by each of these

  • Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administration

 
      captcha refresh

I have read and accept terms and conditions and privacy policy

Cancel
License Details
Electronic PDF copy delivered via email. Report can be used by individual purchaser only.
Single User Licence
$3995
Electronic PDF copy delivered via email. Report can be shared by unlimited users within one corporate location, e.g. a regional office.
Site Licence
$7990
Electronic PDF copy delivered via email. Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company.
Global Licence
$11985
Email to a colleague Request Sample Pages Enquire Before Buying
Prefer to speak to a team member? Call us on:
+44 161 359 5414
Or click here to contact us
Secure Payments
Cards